NCT00078494View on ClinicalTrials.gov

Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

May 31, 2006

Conditions
Nasopharyngeal Neoplasms
Interventions
DRUG

EBV-LMP-2

Trial Locations (1)

20892

National Institutes of Health Clinical Center (CC), Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00078494 - Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter